Latest Property Portfolio News

Mesoblast has entered agreements to issue up to US$50 million in convertible notes, aiming to strengthen its capital base and support pipeline growth, pending shareholder approval.

4DS Memory Limited posted a $9.68 million loss for FY2025 as it advanced its 20nm ReRAM technology, encountering manufacturing setbacks that prompted a detailed root cause analysis. The company secured $8 million in capital to support ongoing development and strategic partnerships.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Patrys Limited reported a 14.9% reduction in net loss for FY2025, driven by lower R&D expenses and tax incentives, while impairing key PAT-DX1 assets and shifting focus to PAT-DX3 development.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

DGL Group reported a modest revenue rise but faced a significant earnings dip in FY25, driven by losses in its Environmental division and restructuring costs. The company is now focusing on integration and operational efficiencies to rebound in FY26.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

Waypoint REIT reported steady distributable earnings for the first half of 2025 alongside a significant rise in statutory net profit, while extending debt facilities and launching a $50 million buyback program.

Harvey Norman Holdings Limited reported robust FY25 results with strong sales growth, a significant profit increase, and a major boost from property revaluations. The company’s integrated retail, franchise, and property model continues to underpin its expansion and resilience.

Harvey Norman Holdings reported a robust 39% jump in profit before tax for FY25, driven by strong franchise sales, a booming property portfolio, and strategic international expansion.

Harvey Norman Holdings Limited reported strong FY25 financial results, driven by growth in franchisee sales, property portfolio appreciation, and digital investments. The company’s integrated retail, franchise, property, and digital system across multiple countries underpins its sustained shareholder returns.